Corrigendum To The Relative Alregime Of 19/2015 January 19, 2015 # Determines New Listings And Price As A Result Of New Therapeutic Indications Of A Medicinal Product For Human Use "simponi (Golimumab). (Resolution No. 130/2015).

Original Language Title: Rettifica della determina n. 19/2015 del 19 gennaio 2015 relativa alregime di rimborsabilita' e prezzo a seguito di nuove indicazioniterapeutiche del medicinale per uso umano Ā«SimponiĀ» (golimumab).(Determina n. 130/2015).

Read the untranslated law here: http://www.gazzettaufficiale.it/atto/serie_generale/caricaArticoloDefault/originario?atto.dataPubblicazioneGazzetta=2015-03-03&atto.codiceRedazionale=15A01367&elenco30giorni=false&atto.tipoProvvedimento=DECRETO

The DIRECTOR-GENERAL having regard to determining # 19/2015 of January 19, 2015 concerning a medicinal product for human use SIMPONI (golimumab) published in the official journal-General series-# 22 of January 28, 2015; Considered the documentation to this Office;
Correction: in art. 2 (for the purpose of Classification) where it is written: for the therapeutic indications rheumatoid arthritis (RA), psoriatic arthritis (AP), ankylosing spondylitis (SA): rheumatologist; Read: therapeutic indications for rheumatoid arthritis (RA), psoriatic arthritis (AP), ankylosing spondylitis (SA): rheumatologist, internist;
Rome, February 11, 2015 Director General: Pani